Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pemetrexed - Eli Lilly and Company

Drug Profile

Pemetrexed - Eli Lilly and Company

Alternative Names: Alimta; LY-231514; LY-231514 disodium; MTA; Multitargeted antifolate; Pemetrexed disodium

Latest Information Update: 28 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly; Eli Lilly and Company; John Wayne Cancer Institute; Merck Sharp & Dohme; University of California, Davis; Virginia Commonwealth University
  • Class Antineoplastics; Benzamides; Glutamates; Hypoxanthines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Antimetabolites; Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mesothelioma; Non-small cell lung cancer
  • Phase II Breast cancer
  • Phase I/II Solid tumours
  • No development reported Chordoma; Head and neck cancer; Non-Hodgkin's lymphoma; Osteosarcoma; Ovarian cancer; Renal cell carcinoma
  • Discontinued Small cell lung cancer

Most Recent Events

  • 28 Oct 2022 No recent reports of development identified for phase-I development in Chordoma in USA (IV, Infusion)
  • 09 Sep 2022 Updated efficacy and adverse events data from the phase III KEYNOTE-189 trial in Non-small cell lung cancer presented at the 47th European Society for Medical Oncology Congress (ESMO-2022)
  • 18 Feb 2022 Vitamin regimen patents for pemetrexed expires worldwide
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top